Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03108495 · ClinicalTrials.gov registry record · Phase 2
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
A Phase 2 study, sponsored by Iovance Biotherapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
NCT03108495: Clinical Trial Phase 2 study, sponsored by Iovance Biotherapeutics.
NCT03108495 is a Phase 2 study that was terminated before completion, run by Iovance Biotherapeutics. The registered enrollment target is 210 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03108495, a Phase 2 study, was terminated before completion, sponsored by Iovance Biotherapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
Study Summary
Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma
Primary Outcome
To evaluate the efficacy of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Interventions
- BIOLOGICAL LN-145
- BIOLOGICAL LN-145 + pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2017-06-22 |
| Est. Completion | 2025-08-22 |
| Phase | Phase 2 |
Why NCT03108495 stopped before completion
NCT03108495 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% higher).
The record links to 0 conditions, and to 2 interventions - of which LN-145 is the first listed.
NCT03108495 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03108495 about?
NCT03108495 is a clinical study titled "Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma". Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with...
What is the current status of trial NCT03108495?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2017-06-22. Estimated completion is 2025-08-22.
What interventions are being tested in trial NCT03108495?
The interventions under investigation include: LN-145 (BIOLOGICAL), LN-145 + pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03108495?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03108495's enrollment target sits among peer trials
210 290th of 2000 higher than 1,707 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI